Euroapi S.A. (EAPIF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Euroapi S.A. (EAPIF) trades at $1.17 with AI Score 38/100 (Grade D). Euroapi S. A. is a European company focused on the development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and intermediates. Market cap: $112M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for EAPIF: EAPIF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EAPIF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
EAPIF: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Euroapi S.A. (EAPIF) Healthcare & Pipeline Overview
Euroapi S.A., incorporated in 2021 and based in Paris, develops, manufactures, and distributes active pharmaceutical ingredients (APIs) and intermediates crucial for human and veterinary medicines. With a focus on the healthcare sector, Euroapi faces competitive pressures and financial challenges reflected in its negative P/E ratio.
What Is the Investment Thesis for EAPIF?
Euroapi S.A. presents a complex investment case. The company operates in the essential active pharmaceutical ingredients (API) market. A key value driver is its role in the pharmaceutical supply chain, providing ingredients for both human and veterinary medicines. However, the company's negative P/E ratio of -0.57 and a negative profit margin of -24.8% indicate financial challenges. Growth catalysts include potential expansion of its product portfolio and increased demand for APIs. The company's beta of 0.60 suggests lower volatility compared to the market. Potential risks include competitive pressures from established API manufacturers and the financial performance. Investors should carefully consider these factors when evaluating Euroapi's investment potential.
Based on FMP financials and quantitative analysis
EAPIF Key Highlights
Market Cap of $112M indicates a relatively small company size within the pharmaceutical industry.
- P/E Ratio of -0.57 reflects negative earnings, suggesting the company is currently not profitable.
- Profit Margin of -24.8% highlights significant challenges in achieving profitability.
- Gross Margin of 16.8% indicates the percentage of revenue exceeding the cost of goods sold.
- Beta of 0.60 suggests the stock is less volatile than the overall market.
Who Are EAPIF's Competitors?
EAPIF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CLVLF Clinuvel Pharmaceuticals Limited | $7.27 | +0.00% | $366M | 56 |
| CMVLF Cellectis S.A. | $3.47 | +12.66% | $252M | 51 |
| CYDY CytoDyn Inc. | $0.21 | +3.26% | $282M | 47 |
| DMTRF 3-D Matrix, Ltd. | $2.50 | +0.00% | $320M | 66 |
| IOBCF Ion Beam Applications S.A. | $18.58 | +0.00% | $545M | 51 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.5M | 68 |
| CKMTF Carmat S.A. | $12.75 | -50.96% | $85.2M | 61 |
| QIPT Quipt Home Medical Corp. | $3.65 | +0.00% | $162M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EAPIF's Key Strengths?
Specialized in API development and manufacturing.
- Serves both human and veterinary medicine markets.
- Established presence in the European market.
- Focus on quality and regulatory compliance.
What Are EAPIF's Weaknesses?
Relatively new company (incorporated in 2021).
- Negative profit margin (-24.8%).
- Limited financial resources compared to larger competitors.
- Dependence on pharmaceutical company demand.
What Could Drive EAPIF Stock Higher?
Potential expansion of API product portfolio to address new therapeutic areas.
- Possible strategic partnerships with pharmaceutical companies to co-develop or market APIs.
- Increasing demand for APIs due to the growing global population and prevalence of chronic diseases.
- Efforts to improve operational efficiency and reduce production costs.
- Regulatory approvals for new APIs in key markets.
What Are the Key Risks for EAPIF?
Financial-distress signal — its Altman Z-Score of -0.24 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-24.3%) — the business is not currently generating profit on shareholder capital.
- Intense competition from established API manufacturers with greater resources.
- Fluctuations in raw material prices impacting production costs and profitability.
- Changes in pharmaceutical regulations affecting API development and manufacturing.
- Negative profit margin and financial instability.
- Limited liquidity due to OTC market trading.
What Are the Growth Opportunities for EAPIF?
- Expansion of API Portfolio: Euroapi can expand its portfolio of active pharmaceutical ingredients to cater to a broader range of therapeutic areas. This includes investing in research and development to create new APIs and intermediates, as well as acquiring existing product lines. The global API market is projected to reach $274.9 billion by 2033, presenting a significant opportunity for Euroapi to increase its market share. Timeline: Ongoing.
- Geographic Expansion: Euroapi can expand its geographic reach beyond Europe to tap into new markets in Asia, North America, and Latin America. This includes establishing sales offices, distribution networks, and manufacturing facilities in key regions. The increasing demand for pharmaceuticals in emerging markets presents a significant growth opportunity for Euroapi. Timeline: Ongoing.
- Strategic Partnerships: Euroapi can form strategic partnerships with pharmaceutical companies, research institutions, and other organizations to accelerate its growth and expand its capabilities. This includes collaborating on research and development projects, licensing technologies, and co-marketing products. Strategic partnerships can provide Euroapi with access to new markets, technologies, and expertise. Timeline: Ongoing.
- Focus on Specialty APIs: Euroapi can focus on developing and manufacturing specialty APIs, such as high-potency APIs (HPAPIs) and controlled substances. These APIs require specialized manufacturing capabilities and offer higher profit margins. The growing demand for specialty APIs presents a significant opportunity for Euroapi to differentiate itself from competitors. Timeline: Ongoing.
- Vertical Integration: Euroapi can pursue vertical integration by acquiring or establishing its own manufacturing facilities for key raw materials and intermediates. This would reduce its reliance on external suppliers and improve its control over its supply chain. Vertical integration can also lead to cost savings and improved product quality. Timeline: Ongoing.
What Are EAPIF's Competitive Advantages?
- Specialized manufacturing capabilities for APIs.
- Established relationships with pharmaceutical companies.
- Regulatory expertise in API development and manufacturing.
- Focus on both human and veterinary medicine APIs.
What Does EAPIF Do?
Euroapi SA, established in 2021 and headquartered in Paris, France, specializes in the development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and intermediates. These essential components are used in formulating a wide range of medicines for both human and veterinary applications. As a relatively new entity, Euroapi has quickly positioned itself within the competitive pharmaceutical supply chain, focusing on providing high-quality ingredients to pharmaceutical companies globally. The company's product portfolio includes a diverse array of APIs and intermediates, catering to various therapeutic areas. Euroapi's business model centers around supplying these ingredients to pharmaceutical manufacturers, who then use them to produce finished drug products. Euroapi's geographic reach extends across Europe and beyond, with a focus on serving the needs of pharmaceutical companies in key markets. Euroapi faces competition from other API manufacturers, both large and small, operating on a global scale. The company differentiates itself through its commitment to quality, reliability, and customer service. Despite being a relatively young company, Euroapi has established a presence in the API market and continues to expand its product offerings and customer base. The company's focus on APIs and intermediates positions it as a critical player in the pharmaceutical supply chain, supporting the development and manufacturing of essential medicines.
What Products and Services Does EAPIF Offer?
- Develops active pharmaceutical ingredients (APIs) for human medicines.
- Develops active pharmaceutical ingredients (APIs) for veterinary medicines.
- Manufactures APIs and intermediates used in drug formulations.
- Markets APIs to pharmaceutical companies globally.
- Distributes APIs through its network to reach customers.
- Provides custom synthesis and manufacturing services for specific API needs.
- Offers regulatory support and documentation for its APIs.
How Does EAPIF Make Money?
- Develops and manufactures APIs and intermediates.
- Sells APIs to pharmaceutical companies for drug formulation.
- Generates revenue through API sales volume and pricing.
- Focuses on both human and veterinary medicine APIs.
What Industry Does EAPIF Operate In?
Euroapi S.A. operates within the active pharmaceutical ingredients (API) market, a critical segment of the broader pharmaceutical industry. The API market is characterized by increasing demand, driven by the growing global population and the rising prevalence of chronic diseases. Competition is intense, with numerous players vying for market share. Euroapi's focus on APIs for both human and veterinary medicines positions it in a growing market, but its financial performance needs improvement to compete effectively.
Who Are EAPIF's Key Customers?
- Pharmaceutical companies formulating human drugs.
- Pharmaceutical companies formulating veterinary drugs.
- Generic drug manufacturers.
- Research institutions and universities.
How Euroapi S.A. Is Valued
Euroapi S.A. carries a market capitalization of $112M, placing it in the micro-cap category. Relative to its peer group, EAPIF's quantitative score of 38/100 is below the peer average of 54/100.
Company Profile
Euroapi S.A. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO David Seignolle. EAPIF has traded publicly since 2022.
Key Financial Metrics
Return on equity for Euroapi S.A. stands at -24.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -16.2%, showing how much profit it generates from its asset base. Its free cash flow yield is 37.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -167.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Euroapi S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.24 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Euroapi S.A. revenue of about $739.6M for fiscal 2026, with EPS near $-1.24. The estimate reflects 4 contributing analysts.
EAPIF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Specialized in API development and manufacturing.
- Serves both human and veterinary medicine markets.
- Established presence in the European market.
- Focus on quality and regulatory compliance.
Bear Case
- Relatively new company (incorporated in 2021).
- Negative profit margin (-24.8%).
- Limited financial resources compared to larger competitors.
- Dependence on pharmaceutical company demand.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
EAPIF Latest News
No recent news available for EAPIF.
EAPIF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EAPIF.
Price Targets
Wall Street price target analysis for EAPIF.
EAPIF MoonshotScore
What does this score mean?
The MoonshotScore rates EAPIF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Seignolle
Unknown
Information about David Seignolle's background is not available in the provided context. Without additional data, it is impossible to provide details on his career history, education, or previous roles.
Track Record: Information about David Seignolle's track record is not available in the provided context. Without additional data, it is impossible to provide details on his key achievements, strategic decisions, or company milestones under his leadership.
EAPIF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Euroapi S.A. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, companies in bankruptcy, or those unwilling or unable to meet higher listing standards. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulation and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Low liquidity and high price volatility.
- Higher risk of delisting or trading suspension.
- Difficulty in obtaining accurate and reliable information about the company.
- Verify the company's registration and legal status.
- Obtain and review any available financial statements.
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with applicable regulations.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Company is registered and in good standing with regulatory authorities (if verifiable).
- Company has a functional website and contact information.
- Company provides some level of financial disclosure (if any).
- Company has a clear business model and revenue streams.
- Company's management team has relevant experience in the industry (if verifiable).
Euroapi S.A. Healthcare Stock: Key Questions Answered
What does the AI Score mean for EAPIF?
EAPIF holds an AI Score of 38/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. Euroapi S.A. is a European company focused on the development, manufacturing, and distribution of active pharmaceutical ingredients (APIs) and intermediates. These products are essential …
What does Euroapi S.A. do?
Euroapi S.A. develops, manufactures, and distributes active pharmaceutical ingredients (APIs) and intermediates, which are essential components used in the formulation of medicines for both human and veterinary use. The company operates as a supplier to pharmaceutical companies, providing them with the necessary ingredients to produce finished drug products. Euroapi's market position is focused on providing high-quality APIs and intermediates to meet the demands of the pharmaceutical industry.
What are the main risks for EAPIF?
The main risks for EAPIF include intense competition from established API manufacturers, fluctuations in raw material prices, changes in pharmaceutical regulations, and the company's current negative profit margin. Additionally, as an OTC-traded stock, EAPIF faces risks related to limited liquidity, potential for price volatility, and reduced regulatory oversight. Investors should carefully consider these risks before investing in EAPIF.
What are the key factors to evaluate for EAPIF?
Euroapi S.A. (EAPIF) holds an AI score of 38/100 (low). presents a complex investment case. The company operates in the essential active pharmaceutical ingredients (API) market. Not financial advice.
How frequently does EAPIF data refresh on this page?
EAPIF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven EAPIF's recent stock price performance?
Euroapi S.A. (EAPIF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized in API development and manufacturing. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider EAPIF overvalued or undervalued right now?
Euroapi S.A. (EAPIF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research EAPIF before investing?
Before investing in Euroapi S.A. (EAPIF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding EAPIF to a portfolio?
Key strength of Euroapi S.A. (EAPIF): Specialized in API development and manufacturing. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- AI analysis pending for EAPIF.